IP Library › Patent Application 11675450
Patent Application
App. No. 11/675,450

NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/675,450
Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Claims (16)

1 . A method for reducing a cholinergic influenced secretion, said method comprising administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin in order to reduce a cholinergic influenced secretion.

2 - 5 . (canceled)

6 . A method for treating a smooth muscle disorder, said method comprising administering to the patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin in order to treat a smooth muscle disorder.

7 - 13 . (canceled)

14 . A method for relieving a muscle spasm said method comprising administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin.

15 - 20 . (canceled)

21 . The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

22 . The method of claim 21 , wherein the botulinum toxin is a botulinum toxin type A.

23 . The method of claim 6 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

24 . The method of claim 23 , wherein the botulinum toxin is a botulinum toxin type A.

25 . The method of claim 14 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

26 . The method of claim 25 , wherein the botulinum toxin is a botulinum toxin type A.

27 . A neurotoxic component of a botulinum toxin for use in humans.

28 . The neurotoxic component of claim 27 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.

29 . The neurotoxic component of claim 27 , wherein the neurotoxic component is selected from the group of consisting of botulinum toxin type A, B, C, D, E, F and G neurotoxic components.

30 . The neurotoxic component of claim 29 , wherein the neurotoxic component is the neurotoxic component of a botulinum toxin type A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2007
From: MERZ PHARMA GMBH & CO. KGAA; MERZ PHARMACEUTICALS GMBH
To: ALLERGAN, INC.
Reel/Frame 019831/0865 →